Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation

Overview of attention for article published in Frontiers in immunology, April 2023

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 11 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 33,031 followers.

RT @FrontImmunol: New Research: Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage…

28 Apr 2023

Reply Repost Favourite

New Research: Unique structure of ozoralizumab, a trivalent anti-TNFα NANOBODY® compound, offers the potential advantage of mitigating the risk of immune complex-induced inflammation: Biologics have become an important component of treatment… https://t.co/

15 Apr 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.